Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute on Aging within the National Institutes of Health is forecasting a Notice of Funding Opportunity titled Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine. This initiative seeks to fund integrative, cross-disciplinary projects that scale up mechanistic studies to understand the genomic drivers of Alzheimer's Disease and Related Dementias. The program emphasizes the use of advanced analytical methods, including machine learning, comparative genomic analysis across various ancestries, and cutting-edge tools such as genome editing and spatial omics to identify actionable therapeutic targets for precision medicine. These projects will utilize sophisticated disease models, including human stem cell-based systems and various in vivo and ex vivo models. The funding will be administered under the U01 activity code. While applications are not currently being accepted, this forecast serves as a notification for investigators to establish collaborations and develop responsive projects in preparation for the official solicitation.
General Info
Place of Performance
Not specifiedSet-Aside
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose a program that supports integrative, cross-disciplinary projects aimed at scaling up mechanistic studies to understand the genomic underpinnings of the pathogenesis and progression AD/ADRD.
The proposed research projects will employ interdisciplinary approaches that integrate innovative techniques to dissect the genomic drivers of AD/ADRD. These projects will leverage advanced analytical methods, including machine learning and comparative genomic analysis across multiple genetic ancestries or multiple neurodegenerative diseases, along with cutting-edge tools like genome editing, functional characterization assays, and emerging single-cell and spatial omics technologies. These studies will use sophisticated disease models, such as human stem cell-based systems, ex vivo, and in vivo models that reflect different genetic ancestries, various model organisms, or multiple neurodegenerative conditions. These cross-ancestry, cross-disease, and cross-species approaches will enable a more comprehensive investigation of the genomic drivers of neurodegeneration and neuropathogenesis. Ultimately, this initiative may lead to the identification of actionable therapeutic targets for AD/ADRD, meeting the urgent need for mechanism-driven insights that can guide precision medicine approaches for its treatment.
Applications are not being solicited at this time. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the U01 activity code. Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this new NOFO.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health
Same awarding agency
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
